Novavax announced plans to begin late-stage clinical trials for its coronavirus vaccine candidate. The 30,000-person trial follows earlier studies that the Maryland-based company said demonstrated a “robust immune response.” Interim data from the Phase 3 trials is expected to be available in Q1 of next year.
Extra: Novavax received $1.6B from the US government as part of “Operation Warp Speed.” The company plans to deliver 100M doses in the US if the vaccine is ultimately approved.
The New Paper
This story is from the December 29, 2020 edition of The New Paper – a clear, concise daily briefing that makes fact-first news easy to consume. Try it today.
